Previous 10 | Next 10 |
AVEO Oncology (Nasdaq: AVEO) today announced the appointment of David Crist as Vice President of Sales. In this role, Mr. Crist will be responsible for building out AVEO’s sales force in anticipation of the potential approval and launch of tivozanib, the Company’s next-gen...
The company entered the fiscal with a doubt of being a going concern. NDA finally accepted by FDA in June 2020. Funds arranged for a possible launch and ongoing development. USP of the lead candidate becoming SoC in 3rd- & 4th-line mRCC. For further details see: ...
Eastman Kodak Company (NYSE: KODK ) +42% as independent review says no laws were broken. More news on: Eastman Kodak Company, Myomo, Inc., Pacific Ethanol, Inc., Stocks on the move, , Read more ...
AVEO Oncology (NASDAQ: AVEO ) announces that final results from the Phase 3 TIVO-3 study comparing Fotivda (tivozanib) to Bayer's ( OTCPK:BAYRY ) Nexavar (sorafenib) in renal cell carcinoma (RCC) patients in third- and fourth-line settings were just published in the journal European...
AVEO Oncology (Nasdaq: AVEO) today announced that final overall survival (OS) results from its Phase 3 TIVO-3 study were published in the journal European Urology. TIVO-3 is the Company’s pivotal Phase 3 trial comparing tivozanib, AVEO’s next-generation vascular endothelial gr...
AVEO Oncology (NASDAQ: AVEO ) has regained full global rights to ficlatuzumab, from Biodesix, as well as announced to fund the clinical manufacture of ficlatuzumab for potential Phase 3 trial in head and neck squamous cell cancer (HNSCC), and additional potential developme...
Announces Decision to Fund Clinical Manufacture of Ficlatuzumab for Potential Phase 3 Study and Update to Biodesix Partnership No Change to AVEO Cash Runway Guidance AVEO Oncology (Nasdaq: AVEO) today announced that it has regained full global rights to ficlatuzumab, AVEO’...
AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will participate in two upcoming virtual investor conferences: Baird 2020 Global Healthcare Conference Date: Thursday, September 10 Time: 8:30 AM Eastern Time H.C. W...
AVEO Oncology ( AVEO -4.7% ) has closed tranched, $35M debt facility with Hercules Capital More news on: AVEO Pharmaceuticals, Inc., Healthcare stocks news, , Read more ...
AVEO Pharmaceuticals (NASDAQ: AVEO ) : Q2 GAAP EPS of -$0.42 beats by $0.18 . More news on: AVEO Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
AVEO Pharmaceuticals Inc. Company Name:
AVEO Stock Symbol:
NASDAQ Market:
SEOUL, South Korea, Jan. 19, 2023 (GLOBE NEWSWIRE) -- LG Chem, Ltd. (“LG Chem”) (KOSPI: 051910) today announced that it has completed its previously announced acquisition of AVEO Oncology (“AVEO”), a commercial stage, oncology-focused biopharmaceutical company committe...
BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, announced that at a special meeting of stockholders ...
BOSTON, Jan. 03, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, reminds all AVEO stockholders to vote before AVEO...